Malignant Childhood Neoplasm – Talk Bio

Actionable Insights Powered by AI

Ipsen Secures Ex-US Rights to Day One’s Pediatric Cancer Medication with $111M Upfront Investment

9 months ago talkbio0Tagged Day One, ex-US, Ipsen, Malignant Childhood Neoplasm, rights, tovorafenib, upfront

Ipsen, Day One, Pediatric Cancer, Tovorafenib, Ex-US Rights, $111M Upfront Investment

Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###

11 months ago talkbio0Tagged Accelerated, Approved, Eli, Eli Lilly, LIBRETTO-121 trial, Malignant Childhood Neoplasm, Malignant neoplasm of thyroid, RET-altered, Retevmo, selpercatinib, Solid Neoplasm, United States Food and Drug Administration

Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib